---
title: "Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Terms and abbreviations"
description: "Formulary evidence on Zeleciment rostudirsen (z-rostudirsen, DYNE-251) in Duchenne muscular dystrophy: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/terms-and-abbreviations"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| 10MWR | 10-meter walk/run |
| 4SC | Four-stair climb |
| 6MWD | Six-minute walk distance |
| 6MWT | Six-minute walk test |
| ACE | Angiotensin-converting enzyme |
| AHFS | American Hospital Formulary Service |
| ARB | Angiotensin receptor blocker |
| ASO | Antisense oligonucleotide |
| BLA | Biologics License Application |
| CI | Confidence interval |
| CNS | Central nervous system |
| DMD | Duchenne muscular dystrophy |
| DMD-QoL | Duchenne Muscular Dystrophy Quality of Life measure |
| DYNE-251 | Development code for zeleciment rostudirsen |
| EMA | European Medicines Agency |
| EMQN | European Molecular Genetics Quality Network |
| Fab | Antigen-binding fragment |
| FDA | U.S. Food and Drug Administration |
| FORCE | Dyne Therapeutics antibody-oligonucleotide delivery platform |
| FVC | Forced vital capacity |
| GC | Glucocorticoid |
| HCRU | Healthcare-resource utilization |
| HDAC | Histone deacetylase |
| HR | Hazard ratio |
| HS | Health state |
| HTA | Health technology assessment |
| HUI-2 | Health Utilities Index Mark 2 |
| ICER | Institute for Clinical and Economic Review |
| IV | Intravenous |
| LoA | Loss of ambulation |
| LTE | Long-term extension |
| MAD | Multiple ascending dose |
| MCID | Minimal clinically important difference |
| NSAA | North Star Ambulatory Assessment |
| OLE | Open-label extension |
| PDUFA | Prescription Drug User Fee Act |
| PMO | Phosphorodiamidate morpholino oligomer |
| PPMD | Parent Project Muscular Dystrophy |
| Q1 | First calendar quarter |
| Q4W | Every four weeks |
| REC | Registrational expansion cohort |
| RFF | Rise from floor |
| SD | Standard deviation |
| siRNA | Small interfering RNA |
| SV95C | Stride velocity 95th centile |
| TEAE | Treatment-emergent adverse event |
| TfR1 | Transferrin receptor 1 |
| TTE | Target trial emulation |
| TTR | Time to rise |
| UK | United Kingdom |
| US | United States |
| z-rostudirsen | Zeleciment rostudirsen |

## Related pages
- [Zeleciment rostudirsen (z-rostudirsen): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy.md)
- [Zeleciment rostudirsen (z-rostudirsen): Duchenne muscular dystrophy](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/executive-summary.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Product information and disease description](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/product-information-and-disease-description.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Clinical evidence](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/clinical-evidence.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Economic information and modeling report](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/economics) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/economics.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: References](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/references) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/references.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: prevalence by geography](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/prevalence) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/prevalence.md)
- [Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/cost-effectiveness-analyses.md)
